Immunohistochemistry or IHC
Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…
Read MoreMolecular and Immunohistochemical Characterization of Mesothelioma of the Tunica Vaginalis
Histopathology 2022 April 23 [Link] William J Anderson, Lynette M Sholl, Christopher D M Fletcher, Stephanie Schulte, Li Juan Wang, Fiona M Maclean, Michelle S Hirsch Abstract Aims: Malignant mesothelioma (MM) of the tunica vaginalis (TV) is a rare and aggressive tumor, and the molecular features and staining profile with contemporary immunohistochemical (IHC) biomarkers are…
Read MoreMulticenter study of diffuse pleural mesothelioma. Histopathological and immunohistochemical features
Medicina 2022 [Link] Claudia Poleri, Gabriela Acosta Haab, Nora Falcoff, Gabriela Guman, Liliana Dalurzo, Alejandro Iotti, María Eugenia Martín, Gloria Olmedo, Mercedes Rayá, Atilio Reginatto, Andrea Werbach, Gabriela Demelli, María José Labanca, Laura Leguina, María Florencia Mora Abstract The pathological diagnosis of diffuse pleural mesothelioma (DPM) contributes to treatment selection and clinical trials interpretation. To…
Read MoreSulfated Glycans Recognized by S1 Monoclonal Antibody can Serve as a Diagnostic Marker for Malignant Pleural Mesothelioma
Lung 2022 April 8 [Link] Koki Nakashima, Yasuhiro Sakai, Hitomi Hoshino, Yukihiro Umeda, Hiroto Kawashima, Yoshitaka Sekido, Tamotsu Ishizuka, Motohiro Kobayashi Abstract Purpose: Malignant pleural mesothelioma (MPM) is a malignant neoplasm of the pleura caused by asbestos exposure. For diagnosis of MPM, immunohistochemistry using multiple markers is recommended to rule out differential diagnoses, such as…
Read MoreEvaluation of DNA/RNA quality from cell block of malignant mesothelioma and lung adenocarcinoma
Diagnostic Cytopathology 2022 April 5 [Link] Shigenobu Tatsumi, Mao Takeuchi, Tomomi Fujii, Aya Sugimoto, Yoko Sekita-Hatakeyama, Takeshi Nishikawa, Tomoko Uchiyama, Kohei Morita, Hiroe Itami, Maiko Takeda, Masaharu Yamazaki, Chiho Ohbayashi Abstract Malignant mesothelioma (MM) is a rare and highly lethal tumor that arises from mesothelial tissue on the surface of the chest and abdominal cavity.…
Read MoreAnetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
The Lancet Oncology 2022 April [Link] Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P Van Meerbeeck, Anna K Nowak, George Blumenschein Jr, Jonathan…
Read MoreWell differentiated papillary mesothelioma of the tunica vaginalis: case report
Acta Chirurgica Belgica 2022 March 28 [Link] Brecht Chys, Nico De Graeve, Luc Merckx Abstract Well differentiated papillary mesothelioma (WDPM) is a rare entity making up 0.3-5% of all mesothelioma cases, while manifestations of the tunica vaginalis are even more uncommon. Literature on WDPM is scarce and our understanding is rather limited. Cellular architecture, stromal…
Read MoreBenign multicystic peritoneal mesothelioma occurring in bilateral inguinal canals metachronously: a case report
Surgical Case Reports 2022 March 16 [Link] Hiroyuki Oshikiri 1 2, Yohei Ozawa 3, On Suzuki 4, Masahiro Usuda 4, Go Miyata Abstract Background: Benign multicystic peritoneal mesothelioma (BMPM) is a benign tumor that usually occurs in middle-aged females. Although several published studies have reported the occurrence of this tumor in the abdominal cavity, few…
Read MoreUsefulness of Cyclin D1/Podoplanin Dual Immunohistochemical Stain to Differentiate Malignant Mesothelioma From Reactive Mesothelial Proliferations
American Journal of Clinical Pathology 2022 March 14 [Link] Raghavendra Pillappa, Austin Wiles, Sadia Sayeed, Valentina Robila Abstract Objectives: To examine the potential of cyclin D1/podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations. Methods: Cyclin D1/podoplanin dual immunohistochemistry was performed on 34 surgical cases of reactive mesothelial proliferations, malignant mesothelioma, and…
Read MoreA Defect of Amphiregulin Release Predicted Longer Survival Independently of YAP Expression in Patients with Pleural Mesothelioma in the IFCT-0701 MAPS Phase 3 Trial
International Journal of Cancer 2022 March 9 [Link] Elodie Maille, Jérôme Levallet, Fatéméh Dubois, Martine Antoine, Claire Danel, Christian Creveuil, Julien Mazieres, Jacques Margery, Laurent Greillier, Valérie Gounant, Denis Moro-Sibilot, Olivier Molinier, Hervé Léna, Isabelle Monnet, Emmanuel Bergot, Alexandra Langlais, Franck Morin, Arnaud Sherpereel, Gérard Zalcman, Guénaëlle Levallet Abstract The Hippo pathway effector YAP is…
Read More